Baylor College of Medicine: Biological E. Limited and Baylor COVID-19 Vaccine Begins Clinical Trial in India
November 17, 2020
November 17, 2020
HOUSTON, Texas, Nov. 17 (TNSRes) -- The Baylor College of Medicine issued the following news release on Nov. 16:
Biological E. Limited (BE), a Hyderabad, India-based vaccines and pharmaceutical company, Dynavax Technologies Corporation (Dynavax), a U.S.-based vaccine-focused biopharmaceutical company, and Baylor College of Medicine today announced that BE has initiated a Phase I/II clinical trial of its COVID-19 subunit vaccine candidate following approval from the Drugs Controller . . .
Biological E. Limited (BE), a Hyderabad, India-based vaccines and pharmaceutical company, Dynavax Technologies Corporation (Dynavax), a U.S.-based vaccine-focused biopharmaceutical company, and Baylor College of Medicine today announced that BE has initiated a Phase I/II clinical trial of its COVID-19 subunit vaccine candidate following approval from the Drugs Controller . . .